

ORIGINAL ARTICLE

Relation between Chronic Obstructive Pulmonary Disease and Peripheral Arterial Disease among Construction Workers

U. SIVAKUMAR¹, RINKU GARG², SUNITA NIGHUTE³¹Department of Physiology, Santosh Medical College, Santosh Deemed to be University, Ghaziabad, Delhi NCR, Uttar Pradesh, India²Professor & HOD, Department of Physiology, Santosh Medical College, Santosh Deemed to be University, Ghaziabad, Delhi NCR, Uttar Pradesh, India³Professor & HOD, Department of Physiology, D.V.V.P.F's Medical college, Ahmednagar, Maharashtra, India.

Corresponding Author: U. Sivakumar

ABSTRACT

Introduction: PAD was asymptomatic in a large proportion of COPD patients and was associated with more severe lung disease than in COPD subjects without PAD.

Materials and Methods: This was a Cross-sectional study conducted at Department of Physiology, Santosh Medical College diagnosed with COPD using Spirometry was recruited for the study with a Sample size of 130 patients.

Results: The characteristics of the population for follow-up (n=130) are presented in table 1. The mean Mean±SD was 51.73±6.1 years. The prevalence of never smokers was 21.5%, former smokers were 51.5% and current smokers were 26.9%. In total, 41 out of 130 individuals (31.5%) had PAD based on an ABI of less than 0.6. A statistically significant association was found between COPD and newly diagnosed PAD during follow-up. The association between COPD and incident PAD was stronger (adjusted OR 1.91, 95% CI 1.14–3.21). Stratified analysis by smoking status revealed that the overall association between COPD and newly developed PAD was driven by the ever smoker group.

Conclusion: Subjects with COPD have a higher risk of developing PAD. People with both COPD and PAD have a substantially increased risk of death. Consequently, early detection of PAD and preventive actions in people with COPD should receive more attention in clinical respiratory care.

Keywords: Peripheral Arterial Disease, Chronic Obstructive Pulmonary Disease, Ankle-brachial index.

INTRODUCTION

Chronic obstructive Pulmonary disease (COPD) is a severe lung disease and it is a significant danger to wellbeing of current culture. [1] COPD is characterized as chronic airflow obstruction that is reformist and just somewhat reversible. [2] COPD incorporates persistent bronchitis and pulmonary emphysema. Ongoing bronchitis is a persistent fiery condition in the lungs that makes the respiratory entries be swollen and bothered, and there is an expansion in the bodily fluid and hack creation in the respiratory entry. [3] Increased hack and sputum creation emerge from a natural safe reaction to breathed in poisonous particles and gases of tobacco smoke. [4]

Peripheral supply route infection (additionally called fringe blood vessel illness) is a typical circulatory issue where limited conduits decrease blood stream to appendages. At the point when its foster fringe supply route sickness (PAD), legs or arms — normally legs — don't get sufficient blood stream to stay aware of interest. [5] This may cause side effects, for example, leg torment when strolling (claudication). Fringe corridor infection is likewise liable to be an indication of a development of greasy stores in supply routes (atherosclerosis). [6]

The commonness of Peripheral Arterial Disease (PAD) in people with COPD shows a wide scope of variety relying upon the seriousness of COPD in the examination populace. [7] Its pervasiveness was discovered to be 8% in Asian COPD patients, 8.8% in the German COPD and Systemic Consequences–Comorbidities Network study (COSYCONET investigation) of COPD patients continued in optional consideration and 36.8% in COPD patients hospitalized for an extreme compounding. [8]

PAD was asymptomatic in an enormous extent of COPD patients and was related with more extreme lung sickness than in COPD subjects without PAD. Along these lines, longitudinal examinations exploring the relationship among COPD and occurrence PAD are required. [9] likewise, in spite of the fact that PAD is known to fundamentally affect mortality, it is obscure whether the danger of mortality is higher in patients with both COPD and PAD. [10]

The lower leg brachial record test is a speedy, non-obtrusive approach to check for fringe course illness (PAD). [11] The lower leg brachial list test contrasts the pulse estimated lower leg and the circulatory strain estimated at arm. [12] A low lower leg brachial file number can demonstrate narrowing or blockage of the courses in legs. Lower leg brachial file testing previously and following

strolling on a treadmill should be possible. An activity lower leg brachial file test can evaluate the seriousness of the limited courses during strolling. [13]

MATERIALS AND METHODS

This was a Cross-sectional study This was a Cross-sectional study conducted at Department of Physiology, Santosh Medical College diagnosed with COPD using Spirometry was recruited for the study with a Sample size 130 patients.

Inclusion criteria:

1. Male subjects aged 40-80 years.
2. Construction workers.
3. Ability to comply with the requirements of the protocol and be available for study visits.
4. Willing to participate in the study.

Exclusion criteria:

1. Subjects aged < 40 and >80 years.
2. Except COPD other pulmonary diseases such as Bronchial asthma, asthma- COPD overlap, Interstitial lung disease, bronchiectasis, cystic fibrosis, lung tumor, pulmonary TB, Pneumonia, etc.
3. Any acute peripheral artery diseases i.e. thromboembolic peripheral artery disease.

Anthropometric: The following parameters was assessed from each subject: Height, Weight, BMI, neck circumference, waist circumference(WC), hip circumference.

Spirometry: Patient with history reminiscent of COPD was screened with spirometry for determination of COPD according to GOLD models of COPD. Nitty gritty history of hazard components of improvement of COPD was brought with the definite history of hazard elements of advancement of Peripheral corridor sicknesses. Point by point assessment with unique accentuation on fringe beat, respiratory and cardiovascular framework was done. Spirometry was done in all patients including pre-and post-bronchodilator after 200 mcg of salbutamol inward breath by Metered Dose inhaler (MDI). All subjects will go through fringe vein Doppler with vascular Doppler Probe and Ankle brachial file (ABI) was determined.

Assessment of the ankle brachial pressure index (ABI): Explain the procedure and reassure the patient and ensure that he/she was lying flat and comfortable, relaxed and adequately rested with no pressure on the proximal vessels.

Statistical analysis: To contemplate populace attributes the Chi-

squared test and the autonomous example t-test were utilized to test contrasts between people with or without COPD. We decided the relationship between benchmark COPD and the advancement of PAD (surveyed during a subsequent visit), utilizing strategic relapse after prohibition of people with predominant PAD at gauge. For the relationship among COPD and recently analyzed PAD, we adapted to covariables that were viewed as hazard factors for atherosclerosis and cardiovascular infection. The accompanying potential confounders were thought: old enough, sex, smoking status, smoking term in pack-years, BMI, hypertension, nationality and diabetes mellitus.

RESULTS

The characteristics of the population for follow-up (n=130) are presented in table 1. The mean Mean±SD was 51.73±6.1 years. The prevalence of never smokers was 21.5%, former smokers were 51.5% and current smokers were 26.9%. In total, 41 out of 130 individuals (31.5%) had PAD based on an ABI of less than 0.6.

Table 1: Characteristic of patients

Characteristic	COPD (n=130)
Age years (Mean±SD)	51.73±6.1
BMI kg·m ⁻²	24.32±3.4
Smoking status	
Never	28 (21.5)
Former	67 (51.5)
Current	35 (26.9)
Diabetes mellitus	28 (21.5)
Hypertension	67 (51.5)
HDL/cholesterol ratio	0.24±0.1
ABI	1.03

Table 2: The association between chronic obstructive pulmonary disease (COPD) and the development of peripheral arterial disease (PAD)

Stratification	No PAD	PAD	Model 1 [#] OR (95% CI)	Model 2 [¶] OR (95% CI)
COPD (n=130)	93 (71.5)	37 (28.4)	1.92 (1.16–3.21)	1.91 (1.14–3.21)
Smoking status				
Never smoker (28)	21 (75.0)	7 (25.0)	1.03 (0.26–4.51)	1.23 (0.31–5.61)
Former smoker (67)	46 (68.6)	21 (31.3)	2.13 (1.17–3.56)	1.27 (1.17–3.51)
Current smoking				

A statistically significant association was found between COPD and newly diagnosed PAD during follow-up. The association between COPD and incident PAD was stronger (adjusted OR 1.91, 95% CI 1.14–3.21). Stratified analysis by smoking status revealed that the overall association between COPD and newly developed PAD was driven by the ever smoker group.

DISCUSSION

As far as anyone is concerned, this is the primary longitudinal populace based examination that has researched the relationship among COPD and occurrence PAD, and the impact of PAD on death rates in people with COPD. We saw that people with COPD have a higher danger of creating PAD and that the danger of mortality was most noteworthy in individuals with the two illnesses.

Smoking is a notable danger factor for both COPD and PAD. Nonetheless, in our investigation, the relationship among COPD and PAD remained genuinely huge upon change for total smoking history (in pack-years). Notwithstanding the potential for leftover jumbling or other unmeasured go between of foundational aggravation, for example, tumor corruption factor-α (TNF-α), interleukin-1β (IL-1β) or lattice metalloproteinases, we guess that COPD-related components past smoking and fundamental irritation may add to the beginning of PAD. [14]

COPD and PAD knowingly affect mortality, nonetheless, no examination in the writing has explored the effect of PAD on the

relationship among COPD and all-cause mortality. We noticed a higher danger of mortality in people when COPD and PAD co-happen, in spite of the fact that there was no formal measurable communication between the two sicknesses on a multiplicative scale. The noticed death rates in people with PAD or with COPD are in accordance with writing reports. The European Respiratory Society (ERS) white book revealed an age-normalized death rate for COPD of around 18 for each 100000 occupants each year (to the European Standard Population), while unstandardized all-cause mortality in the subgroup of people with COPD just was 18.4 per 100000 individual years. Likewise, in a gathering of patients with asymptomatic PAD, DIEHM et al. [15] announced a death rate proportion of 1.4 after change for realized cardiovascular danger factors. We noticed a comparable changed risk proportion of 1.4 in our populace, which features the strength of our information.

Our discoveries have significant ramifications for sickness the board. As COPD is related with PAD improvement, with PAD frequently being asymptomatic, patients with COPD may profit with routine ABI evaluating for the convenient analysis of PAD. [16] Apart from its expense viability, early designated screening and treatment of asymptomatic PAD is probably going to further develop wellbeing by forestalling future cardiovascular sickness [17].

The qualities of this examination are the imminent longitudinal plan and the normalized information assortment. Notwithstanding, our investigation additionally has a few constraints. In the first place, data on PAD was just assembled at the investigation community, during study visits, suggesting that real dates of PAD beginning were missing and keeping us from directing an opportunity to-PAD improvement examination. Besides, since spirometry estimations were not regularly acted in the early adjusts of the Rotterdam Study, the episode date for COPD depended exclusively on a clinical determination of COPD and not all clinically analyzed COPD subjects were as yet alive to be affirmed by spirometry at the examination community sometime in the future. Thirdly, despite the fact that we have assessed all accessible known possible confounders of the relationship among COPD and PAD advancement, leftover bewilderment may in any case clarify part of this affiliation. At long last, incorporating patients with two ABI estimations at two resulting visits may prompt a determination towards better people.

CONCLUSION

Subjects with COPD have a higher danger of creating PAD. Individuals with both COPD and PAD have a significantly expanded danger of death. Thusly, early identification of PAD and preventive activities in individuals with COPD ought to get more consideration in clinical respiratory consideration.

There is no Acknowledgement.

Funding Support - No funding support for this study"

Conflict of Interest - No conflict of interest".

REFERENCES

- Halliday A, Bax JJ. The 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J VascEndovascSurg 2018; 55:301–302.
- Tunstall-Pedoe H, Peters SAE, Woodward M, et al. Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC). J Am Heart Assoc 2017; 6: e005967.
- Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J RespirCrit Care Med 2017; 195: 189–197.
- Morgan AD, Rothnie KJ, Bhaskaran K, et al. Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. Thorax 2018; 73: 877–879.
- Portegies MLP, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH, et al. Chronic obstructive pulmonary disease and the risk

- of stroke: the Rotterdam Study. *Am J Respir Crit Care Med* 2016;193:251–258.
6. Kaszuba M, Śliwka A, Piliński R, et al. The comorbidity of chronic obstructive pulmonary disease and peripheral artery disease—a systematic review. *J Chronic Obstruct Pulmon Dis*. 2019;16:292–302.
 7. Terzikhan N, Lahousse L, Verhamme K, et al. COPD is associated with an increased risk of peripheral artery disease and mortality. *ERJ Open Res*. 2018;4(4):00086–2018.
 8. Kunisaki K, Dransfield M, Anderson J, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. *Am J Respir Crit Care Med*. 2018;198(1):51–57.
 9. McDermott M, Tian L, Wunderink R, et al. Pulmonary hospitalizations and ischemic heart disease events in patients with peripheral artery disease. *Vasc Med*. 2017;22(3):218–224.
 10. Houben-Wilke S, Jorres RA, Bals R, Franssen FM, Glasziou S, Holle R, Karch A, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences–Comorbidities Network study. *Am J Respir Crit Care Med* 2017;195:189–197.
 11. Franssen FME, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, et al. Lung function abnormalities in smokers with ischemic heart disease. *Am J Respir Crit Care Med* 2016;194:568–576.
 12. Patel MR, Conte MS, Cutlip DE, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). *J Am Coll Cardiol* 2015; 65: 931–941.
 13. Halliday A, Bax JJ. The 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2018; 55: 301–302.
 14. Tunstall-Pedoe H, Peters SAE, Woodward M, et al. Twenty-year predictors of peripheral arterial disease compared with coronary heart disease in the Scottish Heart Health Extended Cohort (SHHEC). *J Am Heart Assoc* 2017; 6: e005967.
 15. Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences–Comorbidities Network Study. *Am J Respir Crit Care Med* 2017; 195: 189–197.
 16. Morgan AD, Rothnie KJ, Bhaskaran K, et al. Chronic obstructive pulmonary disease and the risk of 12 cardiovascular diseases: a population-based study using UK primary care data. *Thorax* 2018; 73: 877–879.
 17. Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam Study: 2018 update on objectives, design and main results. *Eur J Epidemiol* 2017; 32: 807–850.